CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS

Their core work

CHU de Poitiers is a French university hospital combining clinical care with applied research, particularly in clinical pharmacology. Their H2020 work shows specific expertise in measuring how antibiotics distribute through human tissues using microdialysis — a laboratory and clinical technique that captures drug concentrations directly at the site of infection. They apply PBPK (physiologically-based pharmacokinetic) and PKPD modelling to predict and optimize antibiotic dosing, with documented focus on hard-to-treat infections including gonorrhoea and prostatitis. As a university hospital, they bring both patient access for clinical validation and the analytical infrastructure needed for translational pharmacology research.

What they specialise in

How they've shifted over time

In their first H2020 involvement (Digi-NewB, 2016–2020), CHU de Poitiers played a peripheral third-party role in a neonatal monitoring project — likely providing clinical access rather than driving scientific content, which explains the absence of keywords for that period. By 2019 their engagement deepened: they became a named participant in AB-DiRecT, an antibiotic pharmacokinetics project, contributing specific technical expertise in microdialysis and PK/PD modelling. The trajectory is from passive clinical host to active research contributor in a specialised pharmacology niche.

CHU de Poitiers is moving toward an active research role in translational antibiotic pharmacology — a field under significant pressure due to antimicrobial resistance — suggesting they are positioning as a specialist clinical-research partner for drug development and dosing optimisation projects.

How they like to work

CHU de Poitiers has never led an H2020 project, joining exclusively as participant or third party. With 17 distinct consortium partners across just 2 projects, they operate within mid-to-large international consortia rather than tight bilateral arrangements. This pattern is typical of university hospitals: they are recruited for their clinical infrastructure, patient populations, or specific technical capabilities rather than for project coordination.

Their two projects brought contact with 17 unique partners across 6 countries, suggesting the consortia they joined were geographically distributed, likely pan-European. No pattern of repeat partnerships is detectable from this small dataset.

What sets them apart

CHU de Poitiers offers a combination rarely found in a single institution: clinical patient access for infectious disease indications (including gonorrhoea and prostatitis) paired with in-house microdialysis capability and computational pharmacokinetic modelling. This makes them a credible clinical validation partner for consortia working on new antibiotic compounds or dosing regimens. For antimicrobial resistance-focused projects specifically, a hospital that can both run microdialysis studies and model tissue drug concentrations in one place removes a significant logistical hurdle.

Highlights from their portfolio

• AB-DiRecT
  Their only funded participation (EUR 266,138), this RIA project on antibiotic tissue distribution is the primary evidence base for their pharmacokinetics expertise and represents a direct alignment with antimicrobial resistance priorities.
• Digi-NewB
  Reveals a secondary clinical capability in neonatal care and shows the hospital's willingness to contribute as a third-party clinical site in digital health and monitoring projects outside their pharmacology niche.